VivoSim Labs Inc SEC Filings

VivoSim Labs, Inc. reported an equity award to its Chief Commercial Officer, Lialin Tony Serge. The filing shows an option to purchase 40,000 shares of common stock with an exercise price of $1.78 each, exercisable beginning 08/11/2025 and expiring 08/11/2035. The option vests over four years with 25% vesting on 08/11/2026 and the remainder vesting in 12 equal quarterly installments thereafter. Following the grant the reporting person beneficially owns 40,000 options on a direct basis.

VivoSim Labs, Inc. (VIVS) filed an initial Form 3 reporting that Tony Serge Lialin (address on file) is identified as an officer with the title Chief Commercial Officer. The filing, dated for the event on 08/11/2025, states explicitly that no securities are beneficially owned by the reporting person at the time of this statement. The form was submitted by a single reporting person and includes an exhibit referencing a power of attorney.

VivoSim Labs, Inc. appointed Tony Lialin as Chief Commercial Officer effective August 11, 2025. Mr. Lialin brings more than two decades of commercial experience in life sciences and will lead the company’s go-to-market strategy, partnerships, and expansion of San Diego services that combine organ-specific 3D models with AI-driven analytics. His initial annualized salary is $360,000 with a $10,000 sign-on bonus and eligibility for a performance bonus with a target up to 40% of base salary. The company granted a 40,000-share option under its 2022 Equity Incentive Plan vesting over four years (25% after one year, then quarterly thereafter). The Offer Letter and a press release are filed as Exhibits 10.1 and 99.1, respectively. Employment is at-will and no related-party or family relationships were reported.

VivoSim Labs reports a quarter of continued transition from clinical-stage drug development to a services and preclinical discovery business. Revenue was minimal at $37,000 from royalties while product revenue ceased following the winding down of Mosaic. The company recorded a $2.843 million net loss for the three months ended June 30, 2025 and cash and cash equivalents declined to $9.1 million, with total assets of $11.98 million and working capital of about $7.6 million.

In March 2025 VivoSim sold its FXR program for $10.0 million ($9.0M at closing, $1.0M in escrow and up to $50.0M in milestone payments). Management disclosed substantial doubt about going concern for the next year and expects to require additional financing; it reported net cash used in operations of $3.94 million in the quarter. The company highlights scientific progress: its liver NAM platform showed 87.5% sensitivity and 100% specificity on a test set presented in May 2025. Management forecasts fiscal 2026 operating expenses of $10–11 million and continues to sell shares through its ATM program.